VIVO stock forecast
Our latest prediction for Meridian Bioscience, Inc.'s stock price was made on the Feb. 21, 2020 when the stock price was at 7.74$.
In the short term (2weeks), VIVO's stock price should outperform the market by 1.39%. During that period the price should oscillate between -6.85% and +9.23%.
In the medium term (3months), VIVO's stock price should underperform the market by -4.57%. During that period the price should oscillate between -23.69% and +20.03%.Get email alerts
Create a solid portfolio with VIVO
About Meridian Bioscience, Inc.
Meridian Bioscience, Inc. engages in the development, manufacture, sale, and distribution of diagnostic test kits, antigens, reagents, and related products. It operates through the following segments: Diagnostics and Life Science. The Diagnostics segment consists testing platforms and technologies such as Isothermal DNA Amplification, Rapid Immunoassay, Enzyme-linked Immunoassay, and Anodic Stripping Voltammetry. The Life Science segment distributes bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.
At the moment the company generates 197M USD in revenues.
On its last earning announcement, the company reported a profit of 0.45$ per share.
The book value per share is 4.13$
Three months stock forecastFeb. 21, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|